Wall Street analysts forecast that Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) will post earnings of ($0.55) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Aeglea BioTherapeutics’ earnings. Aeglea BioTherapeutics posted earnings of ($0.41) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 34.1%. The business is expected to issue its next quarterly earnings report on Thursday, March 22nd.

According to Zacks, analysts expect that Aeglea BioTherapeutics will report full-year earnings of ($1.97) per share for the current year. For the next financial year, analysts expect that the business will report earnings of ($2.00) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that cover Aeglea BioTherapeutics.

Aeglea BioTherapeutics (NASDAQ:AGLE) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.07. The company had revenue of $1.26 million during the quarter. Aeglea BioTherapeutics had a negative return on equity of 44.05% and a negative net margin of 527.99%.

Separately, Zacks Investment Research raised Aeglea BioTherapeutics from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research report on Friday, November 10th.

TRADEMARK VIOLATION WARNING: This story was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/11/19/0-55-eps-expected-for-aeglea-biotherapeutics-inc-agle-this-quarter.html.

Institutional investors and hedge funds have recently made changes to their positions in the business. Susquehanna International Group LLP purchased a new stake in Aeglea BioTherapeutics during the 2nd quarter valued at $653,000. Bank of New York Mellon Corp bought a new position in Aeglea BioTherapeutics in the 1st quarter worth $157,000. Vanguard Group Inc. boosted its holdings in Aeglea BioTherapeutics by 9.4% in the 2nd quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after buying an additional 12,966 shares during the period. Finally, Renaissance Technologies LLC bought a new position in Aeglea BioTherapeutics in the 1st quarter worth $270,000. Institutional investors and hedge funds own 47.52% of the company’s stock.

Shares of Aeglea BioTherapeutics (NASDAQ:AGLE) traded down $0.20 on Friday, hitting $4.54. The stock had a trading volume of 31,117 shares, compared to its average volume of 50,935. Aeglea BioTherapeutics has a 12-month low of $2.81 and a 12-month high of $10.34.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Get a free copy of the Zacks research report on Aeglea BioTherapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.